ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026)

ArriVent BioPharma has disclosed Return on Capital Employed across 3 years of filings, most recently posting 49.61% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 49.61%, up 1084.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 49.61% (up 1084.0% YoY), and the FY2025 annual result was 63.84%, down 1709.0% from the prior year.
• Return on Capital Employed came in at 49.61% for Q1 2026 at ArriVent BioPharma, up from 58.42% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 28.15% in Q2 2024 to a low of 66.56% in Q2 2025.
• The 3-year median for Return on Capital Employed is 49.61% (2026), against an average of 47.27%.
• Across the five-year window, Return on Capital Employed plunged 3841 bps in 2025 and jumped 1084 bps in 2026, its largest moves.
• ArriVent BioPharma's Return on Capital Employed stood at 35.38% in 2024, then sank by 65 bps to 58.42% in 2025, then advanced by 15 bps to 49.61% in 2026.
• The last three Return on Capital Employed figures came in at 49.61% (Q1 2026), 58.42% (Q4 2025), and 58.75% (Q3 2025), per Business Quant data.